Evidence Hub

In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus

Yu Q, Niu X, Hou B, Mao M, Zhu L, Shen W, Wang W

Infection and drug resistance, 2025

Abstract

Objective: This study aimed to evaluate the in vitro antibacterial activity of zifanocycline against Mycobacterium abscessus . Methods: From 2019 to 2024, Mycobacterium abscessus isolates from the respiratory tract of patients were collected at a tertiary hospital in Jiaxing City. All isolates were identified for species, subtypes, and the erm 41 gene polymorphism using whole-genome sequencing (WGS). Susceptibility to zifanocycline and 13 comparators was tested using the broth microdilution method, and the combined effects of zifanocycline and seven antibacterial drugs were evaluated. Results: A total of 67 strains of Mycobacterium abscessus were collected and subjected to whole-genome sequencing. Genomic analysis identified 60 strains of Mycobacterium abscessus subsp. abscessus and 7 strains of Mycobacterium abscessus subsp. massiliense . Among the Mycobacterium abscessus subsp. abscessus strains, 57 exhibited the erm41 T28 genotype, whereas the remaining three showed the erm41 C28 genotype. In our study, zifanocycline (MIC 50 /MIC 90 , 0.06/0.25 mg/L) demonstrated a 2-fold lower MIC 50 and MIC 90 compared to tigecycline (MIC 50 /MIC 90 , 0.12/0.5 mg/L), and a 4-fold and 2-fold lower MIC 50 and MIC 90 , respectively, compared to omadacycline (MIC 50 /MIC 90 , 0.25/0.5 mg/L). In addition to amikacin and linezolid, zifanocycline demonstrated significantly superior antibacterial activity compared with ciprofloxacin, moxifloxacin, trimethoprim–sulfamethoxazole, cefoxitin,…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free